A Phase 3 interventional study of Gonalef® (Follitropin alfa) and Purified pituitary gonadotropin (Fertinorm-P®) in Infertility and Ovulation Induction, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Japan. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2013-12-27.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.
Among the 30 studies testing follitropin alfa in Infertility, this one is the 6th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 10th registered.
2,088 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:
Vietnam Military Medical University · Sites in Vietnam
Ages 18–34 · Women only
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Sites in Japan
Ages 18–42 · Women only
Nanjing University · Sites in China
Ages 35–40 · Women only
By country, each count listing its studies:
follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 20 Years to 39 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 159 across the 30 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 30 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
44 studies in Infertility by Merck KGaA, Darmstadt, Germany: 1 open now, 1 under way, 1 of them phase 3. Of 43 finished, 21 (49%) have results posted.
Among the 44 studies in Infertility by Merck KGaA, Darmstadt, Germany, this one is the 5th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2007, is one of 11 in phase 3, and was the 28th registered.
Merck KGaA, Darmstadt, Germany’s Infertility studies by the year they started, since 1999.
2 of the studies testing follitropin alfa in Infertility that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340827Phase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyA Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) | 2027-09-30 |
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies testing follitropin alfa in Infertility, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 44 in Infertility:
This tab as a report to print or save as PDF → With an account.
Efficacy and safety studies in the past have suggested that a starting dose of 75 International Unit (IU) of SJ-0021, and an increase in the dose by 37.5 IU every 7 days, are safe for treatment of subjects with ovulatory disorders who are infertile due to hypothalamic or pituitary dysfunction and have amenorrhea I or anovulatory cycles (including oligomenorrhea and polymenorrhea).
This was a phase III, multicentre, single-blind, parallel-group comparative study conducted to provide confirmatory evidence of non-inferiority of SJ-0021 versus purified gonadotropin, a comparator drug, for induction of follicle development and ovulation in infertile Japanese women and to provide further information on the safety and tolerability of SJ-0021.
Follicle stimulating hormone (FSH) is a heterodimeric glycoprotein wherein an alfa subunit and a beta subunit are noncovalently bonded. Follicle stimulating hormone is one of the key hormones regulating reproductive functions in both female and male mammals, including humans. In females, it stimulates the development of ovarian follicles, which carry oocytes, while in males it promotes spermatogenesis. Synthesis and secretion of FSH are stimulated by gonadotropin releasing hormone (GnRH), a hypothalamic peptide. Complete or partial deficiencies in FSH secretion are common causes of infertility in men and women. In women, this state is characterized by absence of ovulation or abnormal ovulation. In men, it leads to absence of or abnormally low production of spermatozoa. Administration of FSH, either alone or in combination with luteinizing hormone (LH), has been used successfully to treat these infertility problems. Until recently, only human menopausal gonadotropin (hMG), a mixture of human LH and FSH extracted from the urine of post-menopausal women, and purified FSH (u-hFSH), which could be used to reduce the LH content, had been available for treatment of infertility. In Japan, hMG and u-hFSH are still used to induce ovulation.
Purified pituitary gonadotropin, which was used as the comparator drug in this clinical trial, is a urinary gonadotropin preparation. However, it is not classified as hMG, but rather as a purified pituitary gonadotropin (u-hFSH), and is the preparation most commonly used in Japan. Since the LH content of u-hFSH is very low, it can be administered relatively safely, if adequate care is taken, to patients with polycystic ovary syndrome (PCOS). SJ-0021 is a recombinant human FSH (r-hFSH) that is produced using Chinese hamster ovary (CHO) cells as the host cells. The generic name for SJ-0021 is follitropin alfa for injection, and it is marketed overseas as GONAL-f®. It was approved in Japan in January 2006 as being effective in inducing spermatogenesis in cases of male hypogonadotropic hypogonadism (MHH).
OBJECTIVES
This clinical trial comprised of a pretrial observation period, a treatment period [IMP administration period], and a post-treatment assessment period. The clinical trial was scheduled in such a way that spontaneous menstruation or withdrawal bleeding induced by progesterone administration occurred within 28 days after the completion of baseline tests conducted during the pretrial observation period. A visit to the trial site was then scheduled for any day between Day 2-5 of the spontaneous menstruation or withdrawal bleeding, during which actual registration of the subject for randomization and pre-administration tests were performed. After completion of pre-administration tests, 75 IU of either SJ-0021 or purified pituitary gonadotropin that was allocated to the subject was subcutaneously administered on the same day (dosing Day 1 of treatment period), and the same daily dose was maintained for the first 7 days of the treatment period. On dosing Day 8, the mean diameter of the dominant follicle was measured; if it was \< 11 mm, the daily IMP dose was increased by 37.5 IU and this new daily dose was administered for the next 7 days. If the mean diameter of the dominant follicle was ≥ 11 mm but \< 18 mm, the same (previous) IMP dose was administered for the next 7 days. If the mean diameter of the dominant follicle had already reached 18 mm or above, administration of the IMP was terminated, and the subject moved on to the post treatment assessment period. Similarly, if the mean diameter of the dominant follicle was \< 11 mm on dosing Day 15 or Day 22, the dose was increased; if it was ≥ 11 mm but \< 18 mm, administration was continued at the same previous dose, and if it was ≥ 18 mm IMP administration was terminated. The maximum dose of IMP that can be administered was 187.5 IU/day and the maximum dosing period for the IMP was 28 days. In addition to Day 8, Day 15 and Day 22, ultrasound examination can be conducted once or twice a week during the treatment period, based on the status of growth of the dominant follicle (and on every visit once the dominant follicle has achieved a maximum diameter of 16 mm).
Examinations for the first day of the post-treatment assessment period were conducted, as appropriate, on the day when the mean diameter of the dominant follicle reached ≥ 18 mm or on the day after dosing Day 28 of the IMP. The hCG cancellation criterion (i.e. four or more ovarian follicles with a mean diameter ≥ 16 mm) was also verified at the same time. If the hCG cancellation criterion was not met, a single dose of 5000 IU of hCG was administered intramuscularly, within 24 hours of the last ultrasound examination. Mid-luteal phase tests were conducted on Day 6 ± 1 and Day 9 ± 1 of the post-treatment assessment period, and a final examination was performed on Day 28-31 of the post-treatment assessment period. If the pregnancy test (urine) conducted at this final examination was positive, a further pregnancy test (ultrasound examination) was performed on Day 35-42 of the post-treatment assessment period.
On the other hand, if the mean diameter of the dominant follicle remained \< 16 mm on the day after dosing Day 28 of the IMP, or the hCG cancellation criterion was met, hCG administration was withheld, and the examinations for the first day of the post-treatment assessment period as well as the final examination on Day 28-31 of the post-treatment assessment period were performed accordingly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Gonalef® (Follitropin alfa)
Drug: Purified pituitary gonadotropin (Fertinorm-P®)
Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
Also known as: Gonalef®, follitropin alfa, recombinant human follicle-stimulating hormone, r-hFSH, SJ-0021
Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
Also known as: Fertinorm-P®, purified urinary human follicle-stimulatin hormone, urofollitropin, u-hFSH
Percentage of Participants With Ovulation
Participants were considered to have ovulated if serum progesterone (P4) level was greater than or equal to 5 nanogram (ng)/mL on Day 6±1 or 9±1 during the post-treatment assessment period, or if the participant became clinically pregnant.
Time frame: On Day 6±1 or 9±1 days during post-treatment assessment period (Day 35-42 of post-treatment period for clinical pregnancy)]
Number of Participants With the Dominant Follicle Achieving 18 mm in Mean Diameter
Time frame: Start of treatment period until Day 1 of post-treatment assessment period
Time for Dominant Follicle to Achieve 18 mm in Mean Diameter
Dosing time length was calculated as number of days from the first administration of the IMP until the mean diameter of the dominant follicle was confirmed to have reached 18 mm.
Time frame: Start of treatment period until Day 1 of post-treatment assessment period
Total Dose of the Investigational Medicinal Product (IMP) Administered to Participants With Dominant Follicle Achieving 18 mm in Mean Diameter
Total dose of IMP administered was defined as the cumulative dose administered from the start of treatment with IMP until the mean diameter of the dominant follicle reached 18 mm.
Time frame: Start of treatment period until Day 1 of post-treatment assessment period
Human Chorionic Gonadotropin (hCG) Cancellation Rate
hCG cancellation criterion was defined as the presence of 4 or more ovarian follicles with a mean diameter greater than or equal to 16 mm. If the hCG cancellation criterion was met, the administration of hCG was withheld. Otherwise, a single intramuscular dose of hCG 5000 IU (Japanese Pharmacopoeia- JP) was administered within 24 hours of the last ultrasound examination.
Time frame: Day 1 of post-treatment assessment period
Single Follicle Maturation Rate
Single follicle maturation was defined as the presence of the dominant follicle with a mean diameter of 18 mm or greater without concurrent presence of other follicles of 14 mm or larger in diameter.
Time frame: Start of treatment period until Day 1 of post-treatment assessment period
Biochemical Pregnancy Rate
Biochemical pregnancy was defined as a positive pregnancy test (urinary beta-hCG test) on Day 28-31 of the post-treatment assessment period
Time frame: Day 28-31 of post-treatment assessment period
Clinical Pregnancy Rate
Clinical pregnancy was defined as existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat.
Time frame: Day 35-42 of post-treatment assessment period
Ovulation Rate, Where Ovulation is Defined as a Serum P4 Level Greater Than or Equal to 10 ng/mL or Clinical Pregnancy
For this secondary endpoint, participants were considered to have ovulated if serum P4 level was more than or equal to 10 ng/mL on Day 6±1 or 9±1 during the post-treatment assessment period, or if the participant became clinically pregnant.
Time frame: On Day 6±1 or 9±1 during post-treatment assessment period
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation
AEs: Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs that occur during treatment with the IMP. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. Participants who discontinued from the study due to AE were also recorded.
Time frame: Pretrial observation period to post-treatment assessment period (Days 35-42)
Number of Participants With OHSS
OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
Time frame: Start of treatment period to post-treatment assessment period (Day 35-42)
Participants were recruited in 21 study centers in Japan from 15 February 2007 to 25 December 2007.
| Milestone | SJ-0021 | u-hFSH |
|---|---|---|
| Started | 129 | 136 |
| Treated | 129 | 132 |
| Completed | 123 | 125 |
| Not completed | 6 | 11 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Poor response to treatment | 3 | 1 |
| Withdrew: Other | 2 | 5 |
| Withdrew: Randomized but not treated | 0 | 4 |
Participants were considered to have ovulated if serum progesterone (P4) level was greater than or equal to 5 nanogram (ng)/mL on Day 6±1 or 9±1 during the post-treatment assessment period, or if the participant became clinically pregnant.
| percentage of participants | SJ-0021 | u-hFSH |
|---|---|---|
| Percentage of Participants With Ovulation | 79.1 | 82.6 |
| participants | SJ-0021 | u-hFSH |
|---|---|---|
| Number of Participants With the Dominant Follicle Achieving 18 mm in Mean Diameter | 117 | 125 |
Dosing time length was calculated as number of days from the first administration of the IMP until the mean diameter of the dominant follicle was confirmed to have reached 18 mm.
| days | SJ-0021 | u-hFSH |
|---|---|---|
| Time for Dominant Follicle to Achieve 18 mm in Mean Diameter | 13.1 ± 5.1 | 12.1 ± 4.2 |
Total dose of IMP administered was defined as the cumulative dose administered from the start of treatment with IMP until the mean diameter of the dominant follicle reached 18 mm.
| IU | SJ-0021 | u-hFSH |
|---|---|---|
| Total Dose of the Investigational Medicinal Product (IMP) Administered to Participants With Dominant Follicle Achieving 18 mm in Mean Diameter | 959.29 ± 533.32 | 845.70 ± 432.88 |
hCG cancellation criterion was defined as the presence of 4 or more ovarian follicles with a mean diameter greater than or equal to 16 mm. If the hCG cancellation criterion was met, the administration of hCG was withheld. Otherwise, a single intramuscular dose of hCG 5000 IU (Japanese Pharmacopoeia- JP) was administered within 24 hours of the last ultrasound examination.
| percent hCG cancellation | SJ-0021 | u-hFSH |
|---|---|---|
| Human Chorionic Gonadotropin (hCG) Cancellation Rate | 7.0 | 7.6 |
Single follicle maturation was defined as the presence of the dominant follicle with a mean diameter of 18 mm or greater without concurrent presence of other follicles of 14 mm or larger in diameter.
| percent single follicle maturation | SJ-0021 | u-hFSH |
|---|---|---|
| Single Follicle Maturation Rate | 33.3 | 43.2 |
Biochemical pregnancy was defined as a positive pregnancy test (urinary beta-hCG test) on Day 28-31 of the post-treatment assessment period
| percent biochemical pregnancy | SJ-0021 | u-hFSH |
|---|---|---|
| Biochemical Pregnancy Rate | 17.8 | 15.2 |
Clinical pregnancy was defined as existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat.
| percent clinical pregnancy | SJ-0021 | u-hFSH |
|---|---|---|
| Clinical Pregnancy Rate | 17.1 | 14.4 |
For this secondary endpoint, participants were considered to have ovulated if serum P4 level was more than or equal to 10 ng/mL on Day 6±1 or 9±1 during the post-treatment assessment period, or if the participant became clinically pregnant.
| percent ovulation | SJ-0021 | u-hFSH |
|---|---|---|
| Ovulation Rate, Where Ovulation is Defined as a Serum P4 Level Greater Than or Equal to 10 ng/mL or Clinical Pregnancy | 71.3 | 75.8 |
AEs: Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs that occur during treatment with the IMP. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. Participants who discontinued from the study due to AE were also recorded.
| participants | SJ-0021 | u-hFSH |
|---|---|---|
| TEAEs | 69 | 66 |
| SAEs | 1 | 1 |
| Discontinuation due to AEs | 0 | 1 |
OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
| participants | SJ-0021 | u-hFSH |
|---|---|---|
| Number of Participants With OHSS | 10 | 5 |
Collected over AEs were collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the final post-treatment examination, on Day 35-42 of the post-treatment assessment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SJ-0021 | — | 1/129 (0.8%) | 36/129 (27.9%) |
| u-hFSH | — | 1/132 (0.8%) | 40/132 (30.3%) |
| Event | SJ-0021 | u-hFSH |
|---|---|---|
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 1/129 | 1/132 |
| Event | SJ-0021 | u-hFSH |
|---|---|---|
| Abdominal pain lowerGastrointestinal disorders | 6/129 | 14/132 |
| NasopharyngitisInfections and infestations | 10/129 | 11/132 |
| Abdominal distensionGastrointestinal disorders | 9/129 | 7/132 |
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 9/129 | 4/132 |
| HeadacheNervous system disorders | 6/129 | 8/132 |
| AscitesGastrointestinal disorders | 4/129 | 7/132 |
| Age, Continuous(years) | SJ-0021 | u-hFSH | Total |
|---|---|---|---|
| Mean | 31.6 ± 3.8 | 31.6 ± 3.8 | 31.6 ± 3.8 |
| Sex: Female, Male(Participants) | SJ-0021 | u-hFSH | Total |
|---|---|---|---|
| Female | 129 | 132 | 261 |
| Male | 0 | 0 | 0 |
| Previous episodes of Ovarian hyperstimulation syndrome (OHSS)(participants) | SJ-0021 | u-hFSH | Total |
|---|---|---|---|
| 0 | 116 | 119 | 235 |
| 1 | 9 | 10 | 19 |
| 2 | 2 | 3 | 5 |
| 3 | 1 | 0 | 1 |
| 4 | 1 | 0 | 1 |
The record gives a start of Feb 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin alfa
Merck KGaA, Darmstadt, Germany →